follow us:Google+ FacebookLinkedInTwitterRSS Feeds

advertisement

Generic competition for Singulair takes wind out of Merck's sales

By

Back to Top Comments Email Print

News You Can Use

Latest News

advertisement
The entrance to Merck's Hunterdon County offices. Generic drug competition led to sales drops in the second quarter.
The entrance to Merck's Hunterdon County offices. Generic drug competition led to sales drops in the second quarter. - (NJBIZ file)

Merck & Co Inc. reported an 11 percent drop in sales during the second quarter as increased generic competition pummeled sales of asthma and allergy drug Singulair.

The Hunterdon County drugmaker today reported revenue of $11 billion, down from $12.3 billion in the year-ago quarter.

Singulair represented the biggest drop in the global company's portfolio, declining 80 percent, to $281 million, from $1.4 billion in the second quarter of 2012. Singulair's patent expired last August in the United States and in February for Europe.

Most other Merck drugs reported higher sales, including a 1 percent uptick from diabetes drugs Januvia, its top seller, plus a 16 percent increase from diabetes drug Janumet and an 18 percent rise from Garadsil, a vaccine that treats sexually transmitted cancers.

The increases were not enough to offset the Singulair plunge.

"With seven of our top 10 products growing in the second quarter and solid performance overall, we continue to navigate significant patent expiries and adapt to the global health care environment," CEO Ken Frazier said in a statement.

Outside its pharmaceutical products, Merck reported a 2 percent drop in revenue for its animal health business, to $851 million, and an 11 percent decline in its consumer care business, to $490 million. The company also reported unfavorable exchange rates lowered revenue by 3 percent.

Earnings dropped nearly in half, to 30 cents a share, down from 58 cents a share in the second quarter of 2012. Net income fell to $906 million, from $1.8 billion last year.

Merck said without one-time charges, earnings would have reached 84 cents a share, or $1.1 billion net income.

Merck, based in the Whitehouse Station section of Readington Township, is relocating its headquarters to Summit, a move expected to be complete by 2015.

Shares fell 22 cents to $48.12 in morning trading on the New York Stock Exchange.

Share This Story On:

Write to the Editorial Department at editorial@njbiz.com

advertisement

Comments


Be the first to comment.



Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
     View Comment Policy

Advanced search
Sponsored by
advertisement
  
  
advertisement
  
  
advertisement
Back to Top